Skip to main content
Neyssa Marina, MD, Pediatric Hematology & Oncology, La Jolla, CA

NeyssaMarinaMDMS

Pediatric Hematology & Oncology La Jolla, CA

Executive Medical Director

Dr. Marina is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Marina's full profile

Already have an account?

  • Office

    NA
    La Jolla, CA 92037

Education & Training

  • Stanford University
    Stanford UniversityMS, epidemiology, 2010 - 2011
  • Stanford University
    Stanford UniversityMS, Epidemiology, Magna Cum Laude, 2011
  • University of Tennessee
    University of TennesseeFellowship, Pediatric Hematology/Oncology, 1986 - 1989
  • University of Puerto Rico
    University of Puerto RicoResidency, Pediatrics, 1983 - 1986
  • University of Puerto Rico School of Medicine
    University of Puerto Rico School of MedicineClass of 1983
  • University of Puerto Rico
    University of Puerto RicoBS, Chemistry, 1979

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1995 - 2024
  • TN State Medical License
    TN State Medical License 1986 - 1995
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • America's Top Doctors for Cancer Castle Connolly, 2005-2013, 2016
  • America's Top Doctors Castle Connolly, 2009-2014, 2016
  • Alpha Omega Alpha 1982
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Identification of discrete prognostic groups in Ewing sarcoma  
    Karski EE, McIlvain E, Segal MR, Krailo M, Grier HE, Granowetter L, Womer RN, Meyers PA, Felgenhauer J, Marina N, DuBois SG., Pediatr Blood Cancer, 1/1/2016
  • Pilot Study of Adding Vincristine, Topotecan and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly diagnosed patients with localized Ewing Sarcoma: A Repor...  
    Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N., Pediatr Blood Cancer, 1/1/2016
  • Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children’s Oncology Group  
    Morris CD, Teot LA, Bernstein ML, Marina N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG, Randall RL, J Surg Oncol, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Prognostic factors in children with extragonadal germ cell tumors (GCT): A Pediatric Intergroup Study.
    Marina N, London W, Lauer S, Giller R, Rescorla F, Cushing B, Vinocur C, Malogolowkin M, Castleberry R, Womer R, Med Pediatr Oncol, 1/1/2000
  • Giller R, Cushing B, Lauer S, et al., Proc Am Soc Clin Oncol, 1/1/1998
  • Results of surgery alone or surgery plus cisplatin, etoposide and bleomycin (PEB) in children with localized gonadal malignant germ cell tumors (MGCT): a pediatric Int...
    Cushing B, Giller R, Marina N, Lauer S, Green A, Cullen J, Ablin A, Weetman R, Vinocur C, Rescorla F, Hawkins E, Heifetz S, Rao PV, Krailo M, Castleberry RP, Proc Am Soc Clin Oncol, 1/1/1997
  • Join now to see all

Lectures

  • Update on the Management of Children, Adolescents and Young Adults with Osteosarcoma 
    1/1/2011
  • The Children’s Oncology Group Experience with Dexrazoxane in Pediatric Sarcomas. 
    1/1/2009
  • Treatment Strategies for Osteosarcoma in the Children’s Oncology Group. 
    1/1/2007
  • Join now to see all

Press Mentions

  • Additional Chemotherapy May Not Improve Bone Cancer Outcome
    Additional Chemotherapy May Not Improve Bone Cancer OutcomeAugust 26th, 2016

Professional Memberships

Other Languages

  • Spanish

Industry Relationships

  • Senior Medical Director, Arcus Bioscienced2023 - Present
  • Clinical Lead, Early Oncology Development, Sanofi2021 - 2023
  • Executive Medical Director, Synthorx A Sanofi Company2020 - 2020
  • Executive Medical Directot, Synthorx2019 - 2020
  • Director, Clinical Development, Five Prime Therapeutics2017 - 2019